Research

A Frost & Sullivan report for World Health Expo projects over 10% annual precision medicine growth in the Middle East over the next five to seven

A first clinical cohort of ten blind retinitis pigmentosa patients showed meaningful light sensitivity gains with GenSight's gene therapy and goggle system.

The North Carolina biotech's oral Nrf2/Bach1 modulator HPPD has received FDA Orphan Drug Designation for sickle cell disease, backed by preclinical fetal haemoglobin

The New Haven CNS platform company will use the 36-month grant to push its BrainEx system from 24-hour to two-week intact human

Rezera's RESOLVE-2 Phase 2 trial showed ruvonoflast added significant hsCRP reductions to semaglutide therapy, with no new safety signals observed.

The Leiden spin-out is advancing RTX-001, a once-daily oral pericyte-targeting candidate, toward first-in-human trials in a condition with no

The Brisbane biotech adds at least one new target to its Lilly collaboration, with total milestone-contingent deal value potentially exceeding $870 million.

NorthStrive Biosciences has signed a statement of work with Charles River Laboratories to characterise plasmid copy numbers in its EL-22 and EL-32 engineered

A Spherix Global Insights survey shows physician confidence in autologous CAR-T fell sharply after trial pauses at Novartis and Bristol Myers Squibb.

Joint venture Klothonova has shown GMP-banked Klotho-producing cells remain viable and secrete therapeutic protein inside Cell-in-a-Box capsules.

AAVantgarde Bio presented Phase 1/2 data showing visual function gains in Usher syndrome and strong preclinical support for its Stargardt programme at EURetina 2026.

Climb Bio will present preliminary PrisMN Phase 2 data on budoprutug in membranous nephropathy at ASN Kidney Week in Denver this October.

Phase 1b open-label extension data show no clinically meaningful motor progression in 12 Parkinson's patients after a full year of daily oral rexaceract.

MiNK will present two posters at SITC covering checkpoint-resistant colorectal cancer and senescent tumour-cell clearance using its iNKT platform.

Phase 2 data show Rina-S achieved a 45.9% objective response rate and 12.1-month median duration of response in heavily pretreated platinum

Nonclinical data for the iPSC-derived islet therapy showed consistent manufacturing and durable glycaemic control, with an IND filing due in Q4 2026.

Novo Nordisk presented STEP UP sub-analysis at EASD 2026 showing Wegovy reduced mean liver fat from 8.8% to 3.1% over 72 weeks

Real-world data from nearly 4,000 European type 1 diabetes patients shows Kaleido met consensus time-in-range targets with median hypoglycaemia of just

New EASD 2026 data show CagriSema modifies brain food-cue responses and reduces ectopic fat, with bone health maintained during weight loss.

Egle's IL-2 agonist EGL-003 was well tolerated across four dose cohorts and produced selective Treg expansion, supporting a Q4 2026 atopic dermatitis